312 related articles for article (PubMed ID: 37657307)
1. Post-vaccination SARS-Cov-2 T-cell receptor repertoires in patients with multiple sclerosis and related disorders.
Algu P; Hameed N; DeAngelis T; Stern J; Harel A
Mult Scler Relat Disord; 2023 Nov; 79():104965. PubMed ID: 37657307
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
[TBL] [Abstract][Full Text] [Related]
3. B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control study.
Conte WL
Mult Scler Relat Disord; 2022 Jan; 57():103413. PubMed ID: 35158480
[TBL] [Abstract][Full Text] [Related]
4. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
[TBL] [Abstract][Full Text] [Related]
5. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
[TBL] [Abstract][Full Text] [Related]
6. Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis.
Satyanarayan S; Safi N; Sorets T; Filomena S; Zhang Y; Klineova S; Fabian M; Horng S; Tankou S; Miller A; Krieger S; Lublin F; Sumowski J; Katz Sand I
Mult Scler Relat Disord; 2022 Jun; 62():103737. PubMed ID: 35533419
[TBL] [Abstract][Full Text] [Related]
7. Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies.
Wallach AI; Schiebel M; Picone MA
Mult Scler Relat Disord; 2022 Jul; 63():103856. PubMed ID: 35636275
[TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function.
Sabatino JJ; Mittl K; Rowles WM; McPolin K; Rajan JV; Laurie MT; Zamecnik CR; Dandekar R; Alvarenga BD; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Augusto DG; Alexander JR; DeRisi JL; Hollenbach JA; Wilson MR; Zamvil SS; Bove R
JCI Insight; 2022 Feb; 7(4):. PubMed ID: 35030101
[TBL] [Abstract][Full Text] [Related]
9. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
Tütüncü M; Demir S; Arslan G; Dinç Ö; Şen S; Gündüz T; Uzunköprü C; Gümüş H; Tütüncü M; Akçin R; Özakbaş S; Köseoğlu M; Bünül SD; Gezen O; Tezer DÇ; Baba C; Özen PA; Koç R; Elverdi T; Uygunoğlu U; Kürtüncü M; Beckmann Y; Doğan İG; Turan ÖF; Boz C; Terzi M; Tuncer A; Saip S; Karabudak R; Kocazeybek B; Efendi H; Bilge U; Siva A
Mult Scler Relat Disord; 2023 Jul; 75():104761. PubMed ID: 37247488
[TBL] [Abstract][Full Text] [Related]
10. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
[TBL] [Abstract][Full Text] [Related]
11. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.
Katz JD; Bouley AJ; Jungquist RM; Douglas EA; O'Shea IL; Lathi ES
Mult Scler Relat Disord; 2022 Jan; 57():103382. PubMed ID: 35158475
[TBL] [Abstract][Full Text] [Related]
12. The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders.
Li D; Xu A; Mengesha E; Elyanow R; Gittelman RM; Chapman H; Prostko JC; Frias EC; Stewart JL; Pozdnyakova V; Debbas P; Mujukian A; Horizon AA; Merin N; Joung S; Botwin GJ; Sobhani K; Figueiredo JC; Cheng S; Kaplan IM; McGovern DPB; Merchant A; Melmed GY; Braun J
medRxiv; 2021 Dec; ():. PubMed ID: 34909785
[TBL] [Abstract][Full Text] [Related]
13. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
Front Immunol; 2022; 13():868915. PubMed ID: 35432335
[TBL] [Abstract][Full Text] [Related]
14. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
[TBL] [Abstract][Full Text] [Related]
15. The humoral response to SARS-COV-2 vaccines in MS patients: A case series exploring the impact of DMT, lymphocyte count, immunoglobulins, and vaccine type.
Jakubecz C; Zhang XS; Woodson S; Serra A; Abboud H
Mult Scler Relat Disord; 2022 May; 61():103785. PubMed ID: 35381535
[TBL] [Abstract][Full Text] [Related]
16. Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.
Kister I; Patskovsky Y; Curtin R; Pei J; Perdomo K; Rimler Z; Voloshyna I; Samanovic MI; Cornelius AR; Velmurugu Y; Nyovanie S; Kim JJ; Tardio E; Bacon TE; Zhovtis Ryerson L; Raut P; Pedotti R; Hawker K; Raposo C; Priest J; Cabatingan M; Winger RC; Mulligan MJ; Krogsgaard M; Silverman GJ
Ann Neurol; 2022 Jun; 91(6):782-795. PubMed ID: 35289960
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year.
Disanto G; Galante A; Cantu' M; Sacco R; Mele F; Eisler JJ; Keller F; Bernasconi E; Sallusto F; Zecca C; Gobbi C
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36396447
[TBL] [Abstract][Full Text] [Related]
18. In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.
Achiron A; Mandel M; Dreyer-Alster S; Magalashvili D; Menascu S; Warszawer Y; Dolev M; Didikin M; Harari G; Sonis P; Falb R; Gurevich M
Mult Scler Relat Disord; 2023 Apr; 72():104616. PubMed ID: 36933299
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.
Meyer-Arndt L; Braun J; Fauchere F; Vanshylla K; Loyal L; Henze L; Kruse B; Dingeldey M; Jürchott K; Mangold M; Maraj A; Braginets A; Böttcher C; Nitsche A; de la Rosa K; Ratswohl C; Sawitzki B; Holenya P; Reimer U; Sander LE; Klein F; Paul F; Bellmann-Strobl J; Thiel A; Giesecke-Thiel C
J Neurol Neurosurg Psychiatry; 2022 Sep; 93(9):960-971. PubMed ID: 35835468
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.
Katz Sand I; Gnjatic S; Krammer F; Tuballes K; Carreño JM; Satyanarayan S; Filomena S; Staker E; Tcheou J; Miller A; Fabian M; Safi N; Nichols J; Patel J; Krieger S; Tankou S; Horng S; Klineova S; Beck E; Merad M; Lublin F
Mult Scler Relat Disord; 2023 Feb; 70():104486. PubMed ID: 36628884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]